Ftse Mib
33.746,66
-1,60%
DAX
17.932,17
-1,10%
S&P 500
5.018,39
-0,34%
NASDAQ Composite
15.605,48
-0,33%
Bitcoin
57.148,98
-1,87%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ ESSA Pharma Inc (EPIX) ESSA Pharma Inc (EPIX) Notizie

ESSA Pharma Inc

EPIX
6,62
0,19 (2,95%)
02 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
09/4/202414:00PRNCAESSA Pharma to Present at the 2024 Bloom Burton & Co...
08/3/202402:13PRNUSESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING..
07/3/202423:18EDGAR2Form 8-K - Current report
06/3/202400:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202413:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/2/202413:01EDGAR2Form 8-K - Current report
13/2/202413:00PRNUSESSA Pharma Provides Corporate Update and Reports Financial..
07/2/202417:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202414:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202414:00PRNCAESSA Pharma to Present at the Oppenheimer 34th Annual..
29/1/202415:15EDGAR2Form 8-K - Current report
26/1/202422:40EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
26/1/202422:27EDGAR2Form DEF 14A - Other definitive proxy statements
25/1/202416:00PRNUSESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386)..
23/1/202422:09EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
18/1/202402:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/1/202422:19EDGAR2Form 144 - Report of proposed sale of securities
16/1/202419:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202402:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:04EDGAR2Form 144 - Report of proposed sale of securities
12/12/202313:01EDGAR2Form 8-K - Current report
12/12/202313:00EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
12/12/202313:00PRNCAESSA Pharma Provides Corporate Update and Reports Financial..
24/11/202317:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202314:00PRNUSESSA Pharma to Present at the Piper Sandler 35th Annual..
08/11/202314:00PRNCAESSA Pharma to Present at the Jefferies London Healthcare..
06/11/202323:51PRNUSESSA Pharma Enters into At-The-Market Equity Offering Sales..
06/11/202322:57EDGAR2Form 8-K - Current report
26/10/202323:41PRNUSESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386)..
23/10/202322:19EDGAR2Form 8-K - Current report
21/10/202315:00PRNCAESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386)..
11/10/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
03/10/202322:35EDGAR2Form S-3/A - Registration statement under Securities Act of..
19/9/202322:43EDGAR2Form S-3 - Registration statement under Securities Act of..
18/9/202313:05EDGAR2Form 8-K - Current report
18/9/202313:00PRNUSESSA Pharma Announces Initiation of Phase 2 Study Evaluating..
31/8/202313:00PRNCAESSA Pharma Insiders Establish Automatic Securities..
08/8/202313:15EDGAR2Form 8-K - Current report
08/8/202313:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202313:00PRNCAESSA Pharma Provides Corporate Update and Reports Financial..
06/6/202313:00PRNUSESSA Pharma Appoints Lauren Merendino to its Board of..
01/6/202313:00PRNUSESSA Pharma to Present at 2023 Jefferies Healthcare..
11/5/202313:00PRNCAESSA Pharma to Present at JMP Securities Life Sciences..
09/5/202313:00PRNUSESSA Pharma Provides Corporate Update and Reports Financial..
Apertura: 6,46 Min: 6,43 Max: 7,13
Chiusura: 6,43

La tua Cronologia

NASDAQ
EPIX
ESSA Pharma
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network